ClinicalTrials.gg
Not yet recruitingNCT07851337GEODEUpdated Oct 1, 2026

Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy

A Phase 2 interventional study of - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml in HIV - Human Immunodeficiency Virus, sponsored by ANRS, Emerging Infectious Diseases. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to evaluate the immunomodulatory effects of glatiramer acetate (GA) in improving the recovery of CD4 T cells and the CD4/CD8 ratio in people living with HIV (PLWHIV) who have poor immune recovery and persistent immune activation, despite virologically effective antiretroviral (ARV) treatment.

ANRS 0766s GEODE is a Pilot, multicenter, randomised and open-label clinical trial:

Participants will be randomized 2:1 to either one of the two parallel arms

  • Arm A (24 participants) : Glatiramer Acetate (GA)
  • Arms B (12 participants) : control

Randomisation of the trial arms:

The participants will be randomised in an open-label trial in a 2:1 ratio with, for each arm, a distribution by age group (\< 50 and = or > 50 years) using a minimisation randomisation method.

The trial will consist of three phases:

Phase I: A first controlled phase in which participants in arm A will receive subcutaneous injections of GA three times a week for 16 weeks, and will be compared with participants randomised to arm B who do not receive GA (control group). The primary endpoint will be assessed at week 16 (end of the controlled phase).

Phase II: A second post-interventional observational phase will begin after W16 to evaluate a potential post-treatment effect and its duration in arm A.

During this phase, the efficacy of the strategy during the phase I will be analysed for all participants (once the last randomised participant has reached week 16).

It will continue until the potential opening of the phase III extension, in the event of efficacy be confirmed, or until the decision to terminate the trial if this is not the case.

Phase III: An optional third extension phase may be offered to participants in both arms. The opening of this phase will be conditional upon prior demonstration of a global benefit between both treatment groups during Phase I. During this optional phase III, participants in arm A will be offered a second cycle of GA and those in arm B, a first cycle of GA at the same frequency as a subcutaneous injection three times a week for 16 weeks. Participation in this phase will be optional.

All participants will continue their current antiretroviral treatment.

02

Conditions studied

  • HIV - Human Immunodeficiency Virus

Browse trials for

Keywords

  • HIV
  • glatiramer acetate
  • IMMUNOTHERAPY
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's planned enrollment of 36 is below the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Âge > or = to 18 years,
  • -1 infection,
  • Receiving ART,
  • Have a sustained HIV-1 plasma viral load \<50 copies/mL on ART for more than 3 years (blips \<400 copies/mL allowed),
  • Have a blood \<500 cells/μL (at the last three time points analyzed, including the screening visit, in the 18 months),
  • Have a blood CD4/CD8 T cell ratio \<0.5 (at the last three time points analyzed, including the screening visit, in the past 18 months),
  • Willing to receive treatment via subcutaneous injections three times a week, to adhere to the study schedule, and to accept blood samples in accordance with the protocol,
  • Informed and written consent signed by the participant and the investigator (no later than the day of the enrolment visit and prior to any examination to be carried out as part of the trial) (Article L1122-1-1 of the Public Health Code),
  • Participant covered by health insurance (Article L1121-11 of the Public Health Code).

Exclusion criteria

Exclusion Criteria:

  • -2 infection,
  • Age >65 years (to avoid lack of immune reconstitution due to immunosenescence),
  • to glatiramer acetate or to its : mannitol,
  • Current treatment with systemic , or during the 12 weeks prior to randomisation,
  • Current treatment with , or during the 12 weeks prior to randomisation,
  • History of chemotherapy or radiation therapy (any date),
  • History of hematologic disorders (e.g. lymphoma, leukemia, Bone marrow transplant, solid organ transplant),
  • History of cancer (except cancer that was cured by surgery alone more than 5 years ago; cutaneous epidermoid carcinoma; carcinoma in situ; Kaposi sarcoma that resolved without chemotherapy or radiation therapy),
  • Chronic (positive HBs antigen) or (positive HCV RNA); cirrhosis (including non-viral causes),
  • Active opportunistic infections with risk of severe immune reconstitution inflammatory syndrome (tuberculous neuromeningitis or cryptococcal neuromeningitis),
  • Pregnancy or intention to be pregnant during the study period
  • Participation in any other clinical trial of an agent or in any interventional or non-interventional study requiring additional blood sampling. Participation in an observational study without additional blood sampling is permitted.
  • Participants under guardianship or curatorship or under judicial protection,
  • Renal failure : \< 30 mL/min/1.73 m² (CKD-EPI formula)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Arm A (24 participants) : GLATIRAMER VIATRIS 40mg/ml

    Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment.

    Drug: - Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml

  • No intervention
    Arms B (12 participants) : control

    Control group (Arm B): The participants will continue their current antiretroviral treatment.

Interventions

  • Drug- Study treatment arm group (Arm A): GLATIRAMER VIATRIS 40mg/ml

    Participants will receive GA via subcutaneous injections (40 mg/ml), three times a week, for 16 weeks in addition to their current antiretroviral treatment. The first injection will be administered in hospital under medical supervision. Subsequent injections will be self-administered by participants at home. An injection pen to facilitate subcutaneous injections will be provided to participants.

06

What researchers measure

Primary outcomes

  1. Change in the CD4/CD8 ratio between W0 and W16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).

    Change in the CD4/CD8 ratio between Week0 and Week16 (intra-patient difference between the CD4/CD8 ratio at Week16 and Week0).

    Time frame: 16Weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 57 non-industry phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 24 months is below that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Oct 1, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 15, 2028
CompletionEst.
Dec 15, 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07851337
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 15, 2028 (estimated)
Completion
Dec 15, 2030 (estimated)
Last update
Oct 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion